Literature DB >> 33776574

Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality.

David Andaluz-Ojeda1, Roberto Gonzalez-Fuentes2, Ivan Cusacovich2, Álvaro Aparisi3, Miguel Marcos4, Cristina Ybarra-Falcón3, Carolina Iglesias-Echevarria3, Maria Lopez-Veloso5, Julio Barraza-Vengoechea5, Carlos Dueñas2, Santiago Antonio Juarros Martínez6, Beatriz Rodríguez-Alonso4, José-Ángel Martín-Oterino4, Miguel Montero-Baladia7, Leticia Moralejo4.   

Abstract

OBJECTIVES: To assess the influence of corticosteroid pulses on 60-day mortality in hospitalized patients with severe COVID-19.
METHODS: We designed a multicenter retrospective cohort study in three teaching hospitals of Castilla y León, Spain (865,096 people). We selected patients with confirmed COVID-19 and lung involvement with a pO2/FiO2<300, excluding those exposed to immunosuppressors before or during hospitalization, patients terminally ill at admission, or those who died in the first 24 hours. We performed a propensity score matching (PSM) adjusting covariates that modify the probability of being treated. Then, we used a Cox regression model in the PSM group to consider factors affecting mortality.
RESULTS: From 2933 patients, 257 fulfilled the inclusion and exclusion criteria. 124 patients were on corticosteroid pulses (250 mg of methylprednisolone for three days), and 133 were not. 30.3% (37/122) of patients died in the corticosteroid pulse group and 42.9% (57/133) in the nonexposed cohort. These differences (12.6%, 95% CI [8·54-16.65]) were statically significant (log-rank 4.72, p = 0, 03). We performed PSM using the exact method. Mortality differences remained in the PSM group (log-rank 5.31, p = 0.021) and were still significant after a Cox regression model (HR for corticosteroid pulses 0.561; p = 0.039).
CONCLUSIONS: This study provides evidence about treatment with corticosteroid pulses in severe COVID-19 that might significantly reduce mortality. Strict inclusion and exclusion criteria with that selection process set a reliable frame to compare mortality in both the exposed and nonexposed groups.
Copyright © 2021 Ivan Cusacovich et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33776574      PMCID: PMC7955656          DOI: 10.1155/2021/6637227

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  44 in total

Review 1.  Genomic and nongenomic effects of glucocorticoids.

Authors:  Cindy Stahn; Frank Buttgereit
Journal:  Nat Clin Pract Rheumatol       Date:  2008-09-02

Review 2.  COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.

Authors:  Kam Wa Chan; Vivian Taam Wong; Sydney Chi Wai Tang
Journal:  Am J Chin Med       Date:  2020-03-13       Impact factor: 4.667

3.  Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza.

Authors:  Emili Diaz; Ignacio Martin-Loeches; Laura Canadell; Loreto Vidaur; David Suarez; Lorenzo Socias; Angel Estella; Bernardo Gil Rueda; José Eugenio Guerrero; Montserrat Valverdú-Vidal; Juan Carlos Vergara; María Jesús López-Pueyo; Mónica Magret; Teresa Recio; Diego López; Jordi Rello; Alejandro Rodriguez
Journal:  J Infect       Date:  2012-01-02       Impact factor: 6.072

4.  High-dose corticosteroids in patients with the adult respiratory distress syndrome.

Authors:  G R Bernard; J M Luce; C L Sprung; J E Rinaldo; R M Tate; W J Sibbald; K Kariman; S Higgins; R Bradley; C A Metz
Journal:  N Engl J Med       Date:  1987-12-17       Impact factor: 91.245

5.  Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz
Journal:  Chest       Date:  1987-12       Impact factor: 9.410

6.  Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study.

Authors:  P Dandona; P Mohanty; W Hamouda; A Aljada; Y Kumbkarni; R Garg
Journal:  Clin Pharmacol Ther       Date:  1999-07       Impact factor: 6.875

7.  Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy.

Authors:  J B Keel; M Hauser; R Stocker; P C Baumann; R Speich
Journal:  Respiration       Date:  1998       Impact factor: 3.580

8.  Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

Authors:  Fatimah S Dawood; Seema Jain; Lyn Finelli; Michael W Shaw; Stephen Lindstrom; Rebecca J Garten; Larisa V Gubareva; Xiyan Xu; Carolyn B Bridges; Timothy M Uyeki
Journal:  N Engl J Med       Date:  2009-05-07       Impact factor: 91.245

9.  Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.

Authors:  G U Meduri; A S Headley; E Golden; S J Carson; R A Umberger; T Kelso; E A Tolley
Journal:  JAMA       Date:  1998-07-08       Impact factor: 56.272

10.  [Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection].

Authors:  José Luis Callejas Rubio; Juan de Dios Luna Del Castillo; Javier de la Hera Fernández; Emilio Guirao Arrabal; Manuel Colmenero Ruiz; Norberto Ortego Centeno
Journal:  Med Clin (Barc)       Date:  2020-05-27       Impact factor: 1.725

View more
  9 in total

Review 1.  Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.

Authors:  Fangwen Zhou; Jiawen Deng; Kiyan Heybati; Qi Kang Zuo; Saif Ali; Wenteng Hou; Chi Yi Wong; Harikrishnaa Ba Ramaraju; Oswin Chang; Thanansayan Dhivagaran; Zachary Silver
Journal:  Future Virol       Date:  2022-06-03       Impact factor: 3.015

2.  Comparison of a Target Trial Emulation Framework vs Cox Regression to Estimate the Association of Corticosteroids With COVID-19 Mortality.

Authors:  Katherine L Hoffman; Edward J Schenck; Michael J Satlin; William Whalen; Di Pan; Nicholas Williams; Iván Díaz
Journal:  JAMA Netw Open       Date:  2022-10-03

3.  Corticosteroids in COVID-19: Optimizing Observational Research through Target Trial Emulations.

Authors:  Katherine L Hoffman; Edward J Schenck; Michael J Satlin; William Whalen; Di Pan; Nicholas Williams; Iván Díaz
Journal:  medRxiv       Date:  2022-06-07

4.  Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone.

Authors:  Moncef Belhassen-García; Antonio Sánchez-Puente; Pedro-Ignacio Dorado-Díaz; Amparo López-Bernús; Jesús Sampedro-Gómez; Raúl Azibeiro-Melchor; Edgard Marcano-Millán; Beatriz Rodríguez-Alonso; María-Elisa Sánchez-Barrado; Ignacio Hernández-García; Ignacio Madruga; Guillermo Hernández-Pérez; Cristina Carbonell; Judit García-Aparicio; Laura Burgos; Eugenia López-Sánchez; Carlos Reina; Ana-María Ramón; Laura Cestero-Ramírez; Fátima Boumhir; Daniel Encinas-Sánchez; María Sánchez-Ledesma; Jacinto Herráez; Patricia Araoz; María-José Sánchez-Crespo; Sandra Rodríguez-Rodríguez; Ana-Elisa Rodríguez-Gude; Miguel-Vicente Sánchez-Hernández; Rafael Borrás; Víctor Sagredo-Meneses; Pedro-Luis Sánchez; Miguel Marcos; José-Ángel Martín-Oterino
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

5.  Favourable outcome of severe COVID-19 patients in hyperinflammatory phase with high dose dexamethasone pulse therapy: A series of 10 cases.

Authors:  Swetalina Pradhan; Shyama Sharma; Anup Kumar; Prabhat Kumar Singh
Journal:  J Family Med Prim Care       Date:  2021-12-27

6.  Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19.

Authors:  Ladan Abbasian; Negar Toroghi; Hamid Rahmani; Hossein Khalili; Malihe Hasannezhad; Fereshteh Ghiasvand; Sirous Jafari; Mohammadreza Salehi; Faeze Salahshour; Mahsa Azadbakhsh Kanaf Gorabi; Fateme Alizade; Sara Ghaderkhani; Maryam Nakhostin
Journal:  Int Immunopharmacol       Date:  2022-03-17       Impact factor: 5.714

Review 7.  The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis.

Authors:  Shukun Hong; Hongye Wang; Zhaolong Zhang; Lujun Qiao
Journal:  Steroids       Date:  2022-03-26       Impact factor: 2.760

8.  Severe COVID-19 during pregnancy treated with pulse corticosteroid therapy and mid-trimester termination: A case report.

Authors:  Thinh N Bui; Nhat M Huynh; Nguyen-Huy Do-Tran; Hoang-Anh Ngo; Hung Tran; Nhan T Nguyen; Tung T Pham; Kha D Le; Thu-Anh Nguyen
Journal:  Case Rep Womens Health       Date:  2022-02-09

9.  Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.

Authors:  David Andaluz-Ojeda; Pablo Vidal-Cortes; Álvaro Aparisi Sanz; Borja Suberviola; Lorena Del Río Carbajo; Leonor Nogales Martín; Estefanía Prol Silva; Jorge Nieto Del Olmo; José Barberán; Ivan Cusacovich
Journal:  World J Crit Care Med       Date:  2022-07-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.